share_log

Stocks of the Hour: Tamboran Resources, Recce Pharmaceuticals, Cooper Metals

Stocks of the Hour: Tamboran Resources, Recce Pharmaceuticals, Cooper Metals

當下股票:坦博蘭資源、瑞斯製藥、庫珀金屬
sharecafe ·  04/25 21:10

Tamboran Resources (ASX:TBN) has announced that the Shenandoah South 1H (SS-1H) well in EP 117 achieved an average 90-day initial production flow rate of 2.9 million cubic feet per day. The flow test at the well indicates that future development wells with lateral lengths of 10,000 feet may be capable of delivering average rates of 17.8 million cubic feet per day over the first 90 days of production. Shares are trading 2.94 per cent higher at 17.5 cents.

Tamboran Resources(澳大利亞證券交易所股票代碼:TBN)宣佈,位於第117集的雪蘭多厄南部上半年(SS-1H)油井實現了平均90天初始產量爲每天290萬立方英尺。該油井的流量測試表明,未來橫向長度爲10,000英尺的開發油井在生產的前90天內可能能夠提供每天1780萬立方英尺的平均產量。股價上漲2.94%,至17.5美分。

Recce Pharmaceuticals (ASX:RCE) has unanimously approved a high dose of 4,000mg in a Phase I/II rapid infusion clinical trial for RECCE 327 (R327) for urinary tract infection, following successful testing at various infusion times and identification of optimum fast infusion time. Six participants, comprising both males and females, will undergo dosing over the coming weeks until completion. Shares are trading 0.73 per cent higher at 69 cents.

Recce Pharmaceuticals(澳大利亞證券交易所股票代碼:RCE)在針對尿路感染的I/II期快速輸液臨床試驗中一致批准了4,000mg的高劑量,此前在不同的輸液時間成功進行了測試並確定了最佳的快速輸液時間。六名參與者,包括男性和女性,將在未來幾周內接受給藥直至完成。股價上漲0.73%,至69美分。

Cooper Metals (ASX:CPM) has completed RC drilling on four regional Cu-Au prospects at the Mt Isa East Project. In total, 12 RC drill holes for approximately 1,800m were completed, with 523 one metre samples sent to the laboratory in Mt Isa. The bulk of the samples have come from the Mafic Sweats South Prospect. Shares are trading 4 per cent higher at 13 cents.

Cooper Metals(澳大利亞證券交易所股票代碼:CPM)已經完成了對伊薩山東部項目的四個區域銅金勘探區的RC鑽探。總共完成了12個約1800米的鋼筋混凝土鑽孔,523個一米長的樣本送到了伊薩山的實驗室。大部分樣本來自Mafic Sweats South Prospect。股價上漲4%,至13美分。

1x1.png?futu_img_keep_extra_domain=1

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論